Beijing Hotgen Biotech Co., Ltd. (SHA:688068)

China flag China · Delayed Price · Currency is CNY
110.55
-0.28 (-0.25%)
Apr 29, 2026, 3:00 PM CST
-13.96%
Market Cap 9.85B
Revenue (ttm) 404.88M
Net Income (ttm) -216.05M
Shares Out 88.83M
EPS (ttm) -2.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,618,774
Average Volume 2,813,626
Open 110.20
Previous Close 110.83
Day's Range 109.22 - 113.40
52-Week Range 97.81 - 262.22
Beta 1.39
RSI 38.72
Earnings Date Apr 25, 2026

About Beijing Hotgen Biotech

Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, including upconversion light, chemiluminescence, sugar capture, microfluidics, and genetic testing for testing of intestinal microorganisms, gastrointestina... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 850
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688068
Full Company Profile

Financial Performance

In 2025, Beijing Hotgen Biotech's revenue was 404.88 million, a decrease of -20.75% compared to the previous year's 510.90 million. Losses were -216.05 million, 13.1% more than in 2024.

Financial Statements

News

There is no news available yet.